@article{oai:air.repo.nii.ac.jp:00004775,
 author = {Matsuzawa, Hisanori and Ohshima, Shigetoshi and Goto, Takashi and Komatsu, Masafumi and Nakane, Kunio and Yagisawa, Hitoshi and Nakajima, Kou and Hoshino, Takao and Kuramitsu, Tomoyuki and Yoneyama, Kazuo and Fujishima, Yuukou and Watanabe, Daisuke and Kataoka, Ei and Segawa, Daisuke and Iijima, Katsunori},
 issue = {1},
 journal = {秋田医学},
 month = {Jun},
 note = {Objective : We conducted a multicenter study in Akita Prefecture, Japan, to characterize the efficacy and safety of sofosbuvir (SOF) plus ribavirin (RBV) therapy in Japanese patients infected with hepatitis C virus (HCV) genotype 2.
Methods : All of the patients were infected with HCV genotype 2. Patients received 12 weeks of treatment with 400 mg of SOF daily plus weight-based RBV (600-1,000 mg daily).
Results : A total of 170 patients were enrolled in this study, and 167 patients were followed for 12 weeks after its completion. Among our patients, 28.2% (48/170) had liver cirrhosis (LC). Overall, 159 patients achieved a sustained virologic response for 12 weeks (SVR12), while 8 showed virologic failure. There were no significant differences in the rates of SVR12 between the chronic hepatitis (CH) and LC patients. No significant differences were noted between the CH and LC patients in the rates of any adverse events.
Conclusion : We found that SOF plus RBV treatment resulted in high rates of SVR12 with a favorable safety and tolerability profile, including patients with cirrhosis.},
 pages = {21--30},
 title = {EFFICACY AND SAFETY OF TREATMENT WITH SOFOSBUVIR PLUS RIBAVIRIN FOR HEPATITS C VIRUS GENOTYPE2},
 volume = {47},
 year = {2020}
}